Dosing Frequency Overview of Common GLP-1 Receptor Agonists Liraglutide Liraglutide treats Type 2 diabetes mellitus (T2DM) as the first daily injectable GLP-1 receptor agonist (GLP-1 RA) (15)(23)
2021;122:p154843
Remarkably, ~5090% reduction of L68Q-hCC staining was observed in five of the treated carriers suggesting that L68Q-hCC is a clinical target for reducing agents
Cao X, Liu R, Liu J, Huo Y, Yang W, Zeng M, et al
We used the methods of Wan et al
Given the wide use of these drugs, these adverse events, although rare, must be considered by patients thinking about using them for weight loss, said first author Mohit Sodhi, a graduate of UBCs experimental medicine program and fourth year UBC medical student studying the adverse events of commonly prescribed medications